W.E. Donoghue & Co. LLC bought a new stake in shares of Johnson & Johnson (NYSE:JNJ) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 45,060 shares of the company’s stock, valued at approximately $6,276,000.
A number of other hedge funds and other institutional investors have also recently modified their holdings of JNJ. Evolution Wealth Advisors LLC purchased a new position in Johnson & Johnson during the 4th quarter worth $40,000. Horan Securities Inc. grew its stake in Johnson & Johnson by 122.3% during the 4th quarter. Horan Securities Inc. now owns 438 shares of the company’s stock worth $56,000 after buying an additional 241 shares during the last quarter. Thor Advisors LLC purchased a new position in Johnson & Johnson during the 1st quarter worth $69,000. FNY Investment Advisers LLC grew its stake in Johnson & Johnson by 594.4% during the 4th quarter. FNY Investment Advisers LLC now owns 500 shares of the company’s stock worth $64,000 after buying an additional 428 shares during the last quarter. Finally, CKW Financial Group grew its stake in Johnson & Johnson by 18.8% during the 4th quarter. CKW Financial Group now owns 810 shares of the company’s stock worth $105,000 after buying an additional 128 shares during the last quarter. 66.82% of the stock is owned by institutional investors and hedge funds.
Several brokerages recently weighed in on JNJ. Zacks Investment Research downgraded Johnson & Johnson from a “buy” rating to a “hold” rating and set a $139.00 target price on the stock. in a research note on Thursday, July 18th. Raymond James dropped their target price on Johnson & Johnson from $147.00 to $146.00 and set an “outperform” rating on the stock in a research note on Wednesday, July 17th. Royal Bank of Canada restated a “buy” rating on shares of Johnson & Johnson in a research note on Tuesday, July 16th. Barclays began coverage on Johnson & Johnson in a research note on Friday, June 21st. They set a “hold” rating and a $140.00 target price on the stock. Finally, Goldman Sachs Group began coverage on Johnson & Johnson in a research note on Tuesday, May 28th. They set a “buy” rating on the stock. Five equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $148.56.
Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, July 16th. The company reported $2.58 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.42 by $0.16. The business had revenue of $20.56 billion during the quarter, compared to analysts’ expectations of $20.39 billion. Johnson & Johnson had a return on equity of 38.63% and a net margin of 20.08%. The company’s revenue for the quarter was down 1.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.10 EPS. Sell-side analysts expect that Johnson & Johnson will post 8.6 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Tuesday, August 27th will be issued a $0.95 dividend. The ex-dividend date of this dividend is Monday, August 26th. This represents a $3.80 annualized dividend and a dividend yield of 2.88%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 46.45%.
In related news, Director Marillyn A. Hewson acquired 3,000 shares of the firm’s stock in a transaction dated Tuesday, June 11th. The stock was acquired at an average price of $139.68 per share, with a total value of $419,040.00. Following the acquisition, the director now directly owns 3,000 shares in the company, valued at approximately $419,040. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 0.23% of the company’s stock.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Further Reading: How much can an individual set aside as a catch-up contribution?
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.